After skin cancer treatment misses late-stage trial goal, Regeneron drops
Corroborated by 6 sources from 6 publishers
TL;DR
Reports differ across sources; according to cnbc.com, the drugmaker's fianlimab-cemiplimab combination did not reach statistical significance in improving progression-free survival (PFS), a measure of how long patients live without their advanced melanoma worsening.
Sources
1
Investing.com News
https://www.investing.com/news/analyst-ratings/bofa-reiterates-regeneron-stock-rating-after-melanoma-trial-miss-93CH-4694648
2
Investing.com News
https://www.investing.com/news/stock-market-news/regeneron-shares-fall-12-on-disappointing-melanoma-trial-data-4694797
3
Yahoo Finance News
https://finance.yahoo.com/sectors/healthcare/articles/regeneron-slides-melanoma-study-misses-101925777.html
4
CNBC 100003114
https://www.cnbc.com/2026/05/18/regeneron-drops-after-skin-cancer-treatment-misses-late-stage-trial-goal.html
5
Yahoo Finance News
https://www.barrons.com/articles/regeneron-stock-melanoma-drug-trial-merck-keytruda-99d0d160?siteid=yhoof2&yptr=yahoo
6
Yahoo Finance News
https://www.wsj.com/health/pharma/regeneron-shares-slide-premarket-after-melanoma-drug-trial-disappoints-1994eb66?siteid=yhoof2&yptr=yahoo
7
Seeking Alpha Market News
https://seekingalpha.com/article/4906080-regeneron-time-to-forget-fianlimab-rating-upgrade?source=feed_all_articles
8
Yahoo Finance News
https://finance.yahoo.com/sectors/healthcare/articles/regeneron-sinks-10-failed-phase-194437033.html
9
CNBC 15838499
https://www.cnbc.com/video/2026/05/18/regeneron-sinks-on-latest-cancer-drug-trial.html